Analysts Set Eagle Pharmaceuticals Inc (EGRX) Price Target at $69.40

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has been assigned an average rating of “Hold” from the nine brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $69.40.

Several research firms recently commented on EGRX. Cantor Fitzgerald reissued a “hold” rating and issued a $58.00 target price on shares of Eagle Pharmaceuticals in a report on Tuesday. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Mizuho reissued a “hold” rating and issued a $50.00 target price on shares of Eagle Pharmaceuticals in a report on Wednesday, April 24th. ValuEngine raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 23rd. Finally, Zacks Investment Research lowered Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Friday, April 19th.

In other Eagle Pharmaceuticals news, CEO Scott Tarriff sold 24,975 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $50.15, for a total transaction of $1,252,496.25. Following the transaction, the chief executive officer now owns 1,500,202 shares of the company’s stock, valued at $75,235,130.30. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 28.20% of the company’s stock.

Hedge funds have recently modified their holdings of the business. Campbell Newman Asset Management Inc. grew its holdings in shares of Eagle Pharmaceuticals by 2.5% during the first quarter. Campbell Newman Asset Management Inc. now owns 9,437 shares of the specialty pharmaceutical company’s stock worth $476,000 after purchasing an additional 234 shares during the last quarter. Capital Impact Advisors LLC grew its holdings in shares of Eagle Pharmaceuticals by 40.9% during the fourth quarter. Capital Impact Advisors LLC now owns 33,939 shares of the specialty pharmaceutical company’s stock worth $1,331,000 after buying an additional 9,855 shares during the last quarter. WINTON GROUP Ltd purchased a new position in shares of Eagle Pharmaceuticals during the fourth quarter worth about $9,552,000. Legal & General Group Plc grew its holdings in shares of Eagle Pharmaceuticals by 65.2% during the third quarter. Legal & General Group Plc now owns 29,330 shares of the specialty pharmaceutical company’s stock worth $2,031,000 after buying an additional 11,572 shares during the last quarter. Finally, Chartwell Investment Partners LLC grew its holdings in shares of Eagle Pharmaceuticals by 38.9% during the fourth quarter. Chartwell Investment Partners LLC now owns 216,187 shares of the specialty pharmaceutical company’s stock worth $8,710,000 after buying an additional 60,578 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors.

NASDAQ:EGRX opened at $58.52 on Monday. The firm has a market capitalization of $814.15 million, a P/E ratio of 28.00 and a beta of 1.67. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.92 and a current ratio of 4.13. Eagle Pharmaceuticals has a 12 month low of $36.03 and a 12 month high of $85.66.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.73 by $0.28. The firm had revenue of $49.80 million for the quarter, compared to analyst estimates of $47.03 million. Eagle Pharmaceuticals had a return on equity of 17.76% and a net margin of 14.96%. Eagle Pharmaceuticals’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.55 earnings per share. Analysts predict that Eagle Pharmaceuticals will post 1.88 EPS for the current fiscal year.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Further Reading: How to trade on quiet period expirations

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.